Abstract: Entinostat (MS-275) is an oral, synthetic benzamide derivative that functions as a selective inhibitor of class I and IV histone deacetylases (HDACs). Recently, its role has expanded significantly into the realm of tumor immunotherapy, where it demonstrates a profound ability to modulate the tumor microenvironment, reverse immune evasion, and resensitize refractory tumors to various treatments. By inducing histone and non-histone protein hyperacetylation, entinostat upregulates tumor-associated antigens, enhances the infiltration and functionality of CD8+ T cells, and suppresses immunosuppressive populations such as myeloid-derived suppressor cells (MDSCs). Clinical and preclinical evidence highlights its synergistic potential when combined with immune checkpoint inhibitors, cancer vaccines, and endocrine therapies. This review synthesizes current literature on the pharmacological activity, molecular mechanisms, structural characteristics, limitations, and future perspectives of entinostat in tumor immunotherapy.
1. Introduction
The regulation of gene expression is a finely balanced process essential for cellular homeostasis, heavily influenced by epigenetic modifications such as histone acetylation and deacetylation [3]. In cancer, aberrant epigenetic silencing via the overexpression of histone deacetylases (HDACs) contributes to tumor progression, immune evasion, and resistance to therapy [4][5]. Entinostat, also known as MS-275, is an oral synthetic benzamide derivative that selectively targets class I and IV HDACs [1]. Unlike pan-HDAC inhibitors, entinostat's selective profile has garnered significant interest for its ability to remodel chromatin structure, activate specific tumor suppressor genes, and modulate immune responses [1]. In the context of tumor immunotherapy, entinostat is emerging as a critical agent capable of reprogramming the tumor microenvironment from a refractory to a non-refractory state—a phenomenon termed "episensitization" [4][7]. By overcoming acquired therapeutic resistance and enhancing immune recognition, entinostat represents a promising frontier in combination cancer therapies.
2. Pharmacological Activity
Entinostat exhibits potent pharmacological activity across various malignancies, particularly in breast cancer and non-small cell lung cancer (NSCLC). In hormone receptor (HR)-positive advanced breast cancer, the phase II ENCORE 301 trial demonstrated that the addition of entinostat to the aromatase inhibitor exemestane significantly improved both progression-free survival (PFS) and overall survival (OS) [1]. This led to a Breakthrough Therapy Designation by the FDA and the initiation of the phase III E2112 registration trial [1].
In the realm of immunotherapy, entinostat actively reverses tumor immune escape. It has been shown to sensitize triple-negative breast cancer (TNBC) and colon cancer models to immunotherapies by increasing the infiltration of tumor-infiltrating lymphocytes (TILs) and CD8+ T cells [2]. Furthermore, entinostat exhibits synergistic pharmacological effects when combined with immune checkpoint inhibitors (ICIs). For instance, in NSCLC patients who previously progressed on ICIs, the combination of entinostat with epigenetic agents or PD-1 inhibitors (like pembrolizumab or nivolumab) has shown encouraging disease control rates, highlighting its role in restoring immune responsiveness [3]. Preclinical models also demonstrate that entinostat, when combined with a cancer vaccine and an IL-15 agonist (N-803), synergistically promotes tumor regression [2].
3. Molecular Mechanism of Action
The primary mechanism of action of entinostat involves the selective inhibition of class I and IV HDACs, which leads to the hyperacetylation of histones. This neutralizes the electrostatic attraction between histones and DNA, relaxing the chromatin structure and allowing the transcriptional activation of previously silenced genes [1][5]. Entinostat also induces the acetylation of non-histone proteins, modulating their localization, degradation, and interaction in the cytoplasm and nucleus [1].
In tumor immunotherapy, entinostat's mechanisms are multifaceted. First, it enhances tumor immunogenicity by upregulating the expression of major histocompatibility complex (MHC) class I and II proteins, co-stimulatory molecules, and tumor-associated antigens such as PSA, brachyury, CEA, MUC1, and tumor testis antigens (e.g., IL13RA2) [2][3]. Second, it alters the immune microenvironment by elevating the expression of T-cell chemokines, interferon genes, and immune checkpoint agonists like ICOSL and GITRL [2][3]. Third, entinostat actively dismantles immunosuppressive networks; it significantly reduces the accumulation and suppressive function of granulocytic and monocytic myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), while downregulating the expression of the inhibitory checkpoint molecule VISTA [1][2][3]. Additionally, entinostat impacts epithelial-mesenchymal transition (EMT) and modulates the expression of E2F and Myc genes, further contributing to tumor growth arrest and immune sensitization [1][2].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail extensive chemical structure-activity relationship mapping, it identifies entinostat (MS-275) as a synthetic benzamide derivative [1]. This specific benzamide scaffold is crucial for its pharmacological profile, distinguishing it from other HDAC inhibitor classes such as hydroxamic acids (e.g., vorinostat, belinostat) or cyclic tetrapeptides (e.g., romidepsin) [5]. The benzamide structure confers a high degree of selectivity for class I and IV HDAC enzymes, avoiding the broader, non-specific inhibition seen with pan-HDAC inhibitors [1]. Furthermore, this structural class provides entinostat with a notably long pharmacokinetic half-life, which allows for a convenient, once-weekly oral dosing schedule that is advantageous for patient compliance and sustained epigenetic modulation [1].
5. Current Limitations
Despite its therapeutic promise, the clinical application of entinostat faces several limitations. Toxicity remains a significant concern; clinical trials have reported adverse events including fatigue, nausea, vomiting, and neutropenia [1][3]. Furthermore, preclinical studies indicate that class I HDAC inhibition with entinostat can disrupt fluid-electrolyte homeostasis, leading to conditions such as polyuria, kidney nitric oxide (NO) deficiency, and increased arterial pressure [6]. Another major limitation is the lack of validated, widespread predictive biomarkers to identify which patients will benefit most from entinostat therapy. Although early studies suggest that protein lysine hyperacetylation in peripheral blood mononuclear cells (PBMCs) may serve as a biomarker for progression-free survival, this requires further prospective validation [1]. Finally, as with many targeted therapies, tumors may eventually develop acquired resistance to HDAC inhibitors through mechanisms that are not yet fully understood, necessitating ongoing research into resistance pathways [3].
6. Future Perspectives
The future of entinostat in oncology lies predominantly in rational combination therapies designed to maximize its episensitization properties. Because entinostat primes the tumor microenvironment, there is immense interest in combining it with immune checkpoint inhibitors (such as anti-PD-1/PD-L1 antibodies) to overcome primary and acquired resistance in solid tumors like NSCLC and breast cancer [2][3]. Triple combination strategies—such as integrating entinostat with cancer vaccines and cytokine superagonists (e.g., IL-15)—are showing profound synergistic efficacy in preclinical models and represent a highly promising clinical frontier [2]. Additionally, combining entinostat with DNA methyltransferase inhibitors (DNMTi) like azacitidine is being explored to achieve comprehensive epigenetic reprogramming [3][7]. The results of ongoing phase III trials, such as E2112, will be pivotal in establishing entinostat's regulatory approval and standardizing its role in the oncological armamentarium [1]. Future efforts must also focus on developing robust predictive biomarkers and novel delivery systems (e.g., nanocarriers) to enhance tumor specificity and mitigate systemic toxicities [3].
